Pushing the Boundaries in CLD | Webinar 2
The Physics and Technology Underlying the Beacon Platform for Cell Line Development
Overview
This session will take a deep dive into the core technology powering the Beacon® platform and its impact on cell line development. We will explore how Optoelectronic Positioning (OEP) technology, AI-based cellular detection, and microfluidic NanoPen® chambers work together to enhance high-precision clone selection—ultimately compressing timelines while improving productivity and quality.
Attendees will gain an understanding of how the Beacon system mimic bioreactor-like conditions and enables multiple sequential assays to assess productivity, stability, and quality attributes with complete automated workflows—all while maintaining FDA-validated monoclonality standards.
Speakers
Or Gadish, Ph.D.
Senior Manager, Applications Research and Development Engineering, Bruker Cellular Analysis
Or Gadish has been instrumental in developing automated assays on the Beacon® platform, including the Bispecific Heterodimer Assay and the OptoSeq 3' mRNA Assay. His background in biomedical engineering focuses on high-throughput functional assays for cellular analysis.
Eric Sackmann, Ph.D.
Director of Product Management, Bruker Cellular Analysis
Eric Sackmann led the development of the Opto® Cell Line Development workflow on the Beacon® platform. His expertise lies in microfluidics, immunology, and biopharmaceutical automation.
Live Webcast Details
Key Takeaways
- Compress Cell Line Development Timelines: How the Beacon platform reduces timelines while selecting more productive clones.
- Advanced Clone Selection: Best in class assays to ensure high-performing clone selection.
- Confidently Submit IND Filings to Regulators: How the system delivers superior end to end monoclonality assurance.